Eisai Seeks To Block Dr Reddy’s Over Belviq Plans In India
Executive Summary
Eisai has moved court against Dr Reddy’s for alleged infringement of its patent on Belviq in India. The case is expected to put the spotlight back on prickly IPR issues, including working of patents.
You may also be interested in...
Court Restrains Dr Reddy’s In Indian Belviq Case
An Indian court has granted an interim injunction against Dr Reddy’s in a case concerning the alleged infringement of Eisai’s patent on Belviq. Dr Reddy’s, however, claims that Eisai is a “patent squatter” and expects to appeal against the order.
India’s Emcure Launches First Generic of Eisai's Halaven, Changing Pricing Scenario
Indian drug company Emcure says it is launching the first generic version of Japanese drugmaker Eisai's Halaven which targets metastatic breast cancer and will undercut the branded drug’s price in the country by nearly half.
Interview: Eisai India Unit’s Pivotal Role As Japan Genericizes
Eisai India chief Dr. Sanjit Singh Lamba outlines the competitive edge that the Japanese group’s Indian site offers under the deal with Nichi-Iko; the site has also never “depended” on active pharmaceutical ingredients from China. In a wide-ranging interview with Scrip, Lamba also discusses recent quality compliance initiatives in India.